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Screening of fetomaternal hemorrhage (FMH) is essential in management of fetomaternal antigen incompatibilities of blood.
The objective in this study was to evaluate the ability of automatic blood analyzer (ABA) to screen FMH, also comparing this
method with flow cytometry (FCM). The contents of fetal red blood cells and fetal hemoglobin were evaluated by FCM and ABA,
respectively, using both blood samples of male adults laced with umbilical cord blood diluted at 1/10, 1/100, 1/1,000, and 1/10,000,
or blood from puerperal women collected within 48 hours following delivery. FCM had better performance (area under curve,
AUC = 0.8723) than ABA (AUC = 0.6569) in detecting fetal blood laced with blood from male adults. At a critical level of 0.5%,
ABA indicated that 27.5% of puerperal women would have FMH while FCM did not detect FMH. Our results showed that ABA
overestimates FMHand disagrees with FCMon indicating puerperal womenwith FMH.ABA is inadequate for being used to screen
for or to measure FMH.
1. Introduction
A correct and rapid detection and quantification of fetoma-
ternal hemorrhage (FMH) is essential for the management
and treatment of RhD discordant pregnancies. The amount
of fetal blood transferred into the maternal blood circulation
determines the prophylactic dose of anti-D immunoglobulin
to prevent isoimmunization during pregnancy and postpar-
tum [1].
FMH is the process of transferring blood from the
fetus to the maternal intravascular compartment due to
chorionic villus bleeding. Isoimmunization may occur in a
RhD negative mother carrying a RhD positive fetus. This
may lead to the production of anti-D antibody causing the
development of hemolytic disease and severe anemia of
the fetus and newborns [2–4]. The purpose of prophylaxis
is to prevent RhD isoimmunization in future pregnancies.
However, prophylaxis is based on the administration of
standard doses of anti-D immunoglobulin which frequently
corresponds to an overtreatment of the patient. Adequate
doses of immunoglobulin rely on the accurate evaluation
of the amounts of fetal blood in women’s circulation, using
methods with limited availability [5].
The first method developed for FMH quantification is a
technique based on acid elution of blood smear, known as
Kleihauer-Betke test [6], which is currently obsolete [6–9].
Flow cytometry (FCM) has become the standard method for
detecting and measuring FMH and is commercially available
as an assay kit. FCM combines cell morphology and conju-
gates of fluorophore molecules with monoclonal antibodies
for multiparametric analysis of specific cell population. FCM
evaluation of FMH is achieved by using anti-HbF and anti-
RhD antibodies to identify a specific group of blood antigens
that act asmarkers for red blood cells (RBC) from fetus. Anti-
HbFmonoclonal antibodies allow the discrimination of three
distinct cell populations: fetal RBCs, F-cells, and adult RBCs.
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FCM identification of F-cells eliminates the disadvantage of
Kleihauer-Betke [10–12].
Automatic blood analyzers (ABA) combine different ana-
lytical procedures into a single device, allowing rapid deter-
mination of multiple blood parameters using a small sample
volume. Automatic blood analyzer is used to define standards
of accuracy, reliability, and performance of blood gas tests by
measuring parameters of pH, electrolytes, metabolites, and
oximetry using spectrophotometry technology as in the case
of fetal hemoglobin dosage [13]. Since it discriminates adult
and fetal hemoglobin, this device is potentially useful for
the evaluation of FMH. Additionally, ABA would represent
a quicker and lower-cost alternative for the assessment of
FMH compared to Kleihauer-Betke and/or FCM [14]. The
objective in this study was to evaluate the ability of ABA to
screen for FMH at critical level of 0.5% which is within the
hemorrhage volumes neutralized by standard doses of anti-
D treatment, also comparing ABA with FCM, a method that
has been replacing Kleihauer-Betke test for this end.
2. Subject and Methods
2.1. Subjects and Blood Collection. Blood samples were col-
lected from 57 male adults weighing more than 50 kg, who
denied hematological pathologies and metabolic diseases.
Blood samples from 14 newborns weighing above 2.5kg
were collected from the umbilical cord just after birth.
Additionally, blood samples from 40 puerperal women were
collected within 48 hours following delivery at Hospital da
Mulher Prof. Dr. José Aristodemo Pinotti (CAISM),Women’s
Hospital at University of Campinas (UNICAMP, Campinas,
Brazil). All blood samples of umbilical cord or puerperal
women were collected from subjects who denied metabolic
or hematological diseases and delivered without obstetric
complications. Blood collections were performed using 10ml
vacuum blood-sampling tubes containing sodium heparin
(Vacuette, Campinas, Brazil). The study was approved by the
Ethical Review Board, Research Ethics Committee of UNI-
CAMP (1.386.253/2016), and was registered on the Brazil-
ian National Health Council (CAAE: 49989315.0.000.5404).
Subjects or their legal guardian received information about
the study and gave written informed consent before blood
sampling.
2.2. Blood Sample Preparation. Blood samples containing
fetal blood were prepared by serially diluting blood taken
from umbilical cord with blood of male adults. Initially,
50𝜇l of umbilical cord blood was laced in 450𝜇l of adult
blood. Subsequently, a tenfold dilution factor was used,
always transferring 50ul for each dilution step and resulting
in blood samples containing fetal blood at dilutions of 1/10,
1/100, 1/1,000, and 1/10,000. This procedure resulted in 285
artificially diluted blood samples, containing from 1 to 1,000
fetal red blood cells per 10,000 adult red blood cells. In
addition, undiluted blood samples of adults and umbilical
cord were also evaluated as negative and positive controls,
respectively.The samples were thoroughly homogenized dur-
ing the dilution process and prior to analysis. Blood samples
from puerperal women were used without any previous
preparation.
2.3. Blood Sample Evaluations. The contents of fetal red
blood cells and fetal hemoglobin in all blood samples (blood
samples from male adults, umbilical cord, puerperal women,
and serially diluted fetal blood samples) were evaluated by
FCM and ABA, respectively. The FMH QuikQuant kit (IQ
Products, Groningen, ME) was employed for the preparation
of blood samples prior FCM based analysis, following the
manufacturer’s recommendations. Initially, serially diluted
blood samples prepared as aforementioned and blood sam-
ples from puerperal women were diluted at 1/20 ratio with
QuikQuant buffer. Then, 10𝜇l of diluted blood samples was
fixed by addition of 0.75ml of glutaraldehyde (0.04% in
PBS; Sigma-Aldrich, Saint Louis, MO). During the period
of fixation (10 minutes at room temperature), samples
were intermittently vortexed. Thereafter, 1.5ml of Trillium
IntraCell  working solution was added to each samples
tube, which remained incubated at room temperature for
10 minutes. Samples were washed by centrifugation and
the supernatants were removed. Cell pellets were suspended
with 10𝜇l of Trillium FMH QuikQuant  reagent, which
contains fluorescein isothiocyanate-conjugated anti-HbF and
propidium iodide, and 40𝜇l QuikQuant  FMH Buffer
working solution to prior incubation for 10 minutes in the
dark. After the incubation period, samples were washed
twice by centrifugation. Data acquisition was performed
using a FACSVerse cytometer with FACSuite software (Bec-
ton Dickinson, San Jose, CA, USA) and a minimum of
50,000 cells were acquired. Data analysis was conducted
using FlowJo software (Version 10; Tree Star, Ashland, OR,
USA).
In parallel, the same blood samples were analyzed on
an ABA ABL800 flex (Radiometer Medical, Brønshøj, Den-
mark). In this equipment, fetal hemoglobin is assessed by
technics based on oximetry and spectrophotometry prin-
ciples and does not require previous preparation of blood
sample.
2.4. Statistics. The profile of the samples according to the
variables under study was assessed by descriptive statistics.
The accuracy of FCM and ABA to detect fetal blood laced
with blood samples from male adults was further evaluated
by plotting the receiver operating characteristic (ROC) curves
for each of the methods. In order to analyze the relation-
ship between the amounts of fetal blood detected by the
two methods (FCM and ABA) the Spearman correlation
coefficient was calculated. Because results included values
equal to zero, all the values obtained by ABA and FCM
were transformed as log
10
(x + 0.5). Logarithmic values
were also used for analyzing the agreement between the
FCM and ABA by Bland-Altman method. The level of
significance was set at p value < 0.05. Statistical calculations
were performed using Prism 6 (GaphPad Software; La Jolla,
CA, USA) and the Statistical Analysis System (SAS) for
Windows, version 9.2 (SAS Institute Inc., 2002-2008, Cary,
NC, USA).





















































































Figure 1: Flow cytometry-based analysis of blood samples, showing the gating strategy. The figure shows a representative sample at 1/10
dilution of umbilical cord blood in blood of male adult. (a) Total blood cells were gated on logarithmic dot plot; (b) nucleated cells were
excluded by gating the propidium iodide (PI) negative cell population. (c) Different red blood cell (RBC) populations were detected and
quantified based on their fetal hemoglobin content. In addition to histogram, events within the gate of fetal RBCs were also evaluated by
plotting the fluorescein isothiocyanate (FITC) channel against phycoerythrin (PE) and side-scatter (SSC) channels to confirm the percentage
of events.
3. Results
3.1. Evaluation of Fetal Blood in SeriallyDiluted Blood Samples.
The main characteristics of the subjects at the time of blood
sampling were shown in Table 1, while Figure 1 depicts the
gating strategy used in flow cytometry-based analysis to
quantify fetal red blood cells in blood samples.
Both methods were able to differentiate between samples
with andwithout fetal blood,while assessing blood samples of
male adults containing fetal blood.However, this capacitywas
limited as dilution of fetal blood increased.Thus, ABA results
were significantly different between sampleswith andwithout
fetal blood up to dilution 1/10, while FCM results were
significantly different up to dilution 1/100 (Supplementary
Table 1).
The accuracy of FCM and ABA to detect fetal blood was
evaluated by plotting the receiver operating characteristic
(ROC) curves for each method (Figure 2 and Supplementary
Figure 1). Overall, FCM (area under curve, AUC = 0.8723)
had better performance than ABA (AUC = 0.6569) to detect
the presence of fetal blood laced with blood of male adults
(Figure 2). Additionally, ABA had lower specificity (59.65%)
and lower negative predictive value (31.78%) compared with
FCM (78.95% and 58.44% respectively), indicating that
assessment of FMH by ABA could be implied in a high
probability of false positive results (Supplementary Table 2).
3.2. Correlation and Agreement between FCM and ABA. The
correlation and agreement between results obtained through
FCM and ABA were further compared following assessment
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Figure 2: Receiver operating characteristic (ROC) curves compar-
ing the performance of ABA and FCM in detecting fetal blood
laced with blood frommale adults. Blood samples were prepared by
serially diluting umbilical cord (n=14) blood in blood of male adults
(n=57) at dilutions 1/10, 1/100, 1/1,000, and 1/10,000, resulting in 285
artificially diluted blood samples, containing from 1 to 1,000 fetal red
blood cells per 10,000 adult red blood cells.




Sex Female 8 - 40
Male 6 57 -
Gestational age
(weeks) 36 (33-41) - -
Age (years) - 18-60 18-42
ABO group
A 5 11 15
B 3 3 4
AB - - 1
O 6 46 20
RhD Positive 14 56 36
Negative 0 4 4
of both blood samples ofmale adults containing fetal blood at
different dilutions (processed as aforementioned) and blood
from puerperal women taken within 48 hours following
delivery. Thus, low correlation (Figure 3(a)) and lack of
agreement (Figure 3(b)) were found between results obtained
by FCM and ABA for samples of male adults containing fetal
blood. Similarly, there was no correlation (Figure 3(c)) or
agreement (Figure 3(d)) between results obtained by FCM
and ABA for the contents of fetal blood in samples from
puerperal women.
FCM and ABA were compared for screening of FMH in
puerperal women, taking into consideration thresholds (Sup-
plementary Table 2) previously specified for these methods
while assessing blood samples from male adults containing
fetal blood. As indicated in Table 2, most of the puerperal
womenwere categorized below the threshold specified for the
lowest dilution of fetal blood. At 1/10 dilution; for example,
80% of the puerperal women (32 in 40) were below the
thresholds established for FCM and ABA. However, as dilu-
tion increased, numbers of puerperal women ranged among
the different classes and revealed a disparity between the two
methods; i.e. ABA and FCM disagreed in indicating the same
set of puerperal women as being above the thresholds. Thus,
at 1/10,000 dilution, ABA indicated 27.5% of the puerperal
women (11 in 40) were above the thresholds while FCM
indicated 17.5% (7 in 40), which comprised a different group
of puerperal women (Table 2). Based on these results, it was
determined that, at a critical level of 0.5%, ABA indicated that
27.5% of puerperal women would have FMH while FCM did
not detect FMH.
4. Discussion
In this study, ABA was evaluated as a screening method
for the detection of FMH. To our knowledge, this was the
first time that such a method is systematically evaluated for
this end. Additionally, accuracy of ABA to detect fetal blood
was also evaluated and compared with FCM. Prevalence
of isoimmunization due to RhD incompatibility between
mother and her fetus has been lowered by the use of
recommended prophylaxis [15]. However, FMH detection
relies on methods with limited availability and, therefore,
new automatized methods could benefit FMH diagnosis and
treatment. Blood evaluation through ABA requires small
amounts of blood and is less dependent on operator’s practice
and less expensive than FCM. Additionally, ABA is more
accessible, since most of the intensive care units have this
equipment [16].
Nevertheless, our results showed that evaluation of blood
through ABA could be implied in overestimation of FMH.
This feature is possibly a consequence of ABA’s failure to
differentiate between red blood cells from fetal blood and F-
cells from adult blood. F-cells are red blood cells from adults
containingHbF. Although these cells can frequently be found
in low amounts in the blood of healthy adults, their numbers
are increased in certain inherited hemoglobin disorders or
in acquired conditions, such as acute erythropoietic stress
and cancer [17–21]. It was also reported that F-cells can
be increased during pregnancy as a result of physiological
response [22]. However, Pastoret et al. [23] established 2.2%
(0.3 to 11.3%) and 3.4% (0.9 to 13.6%) as reference values
of F-cells in pregnant and nonpregnant women, respectively.
Similarly, we have found 2.6% (0.0 to 9.9%) as reference value
of F-cells in blood of male adult donors (data not shown).
Differently, detection of fetal red blood cells by FCM
is based on the specific labeling of HbF by fluorophore-
conjugatedmonoclonal antibodies (anti-HbF) [24, 25]. Addi-
tionally, anti-HbF specificity varies between HbF contained
in fetal red blood cells and F-cells, favoring differentiation not
only fetal red blood cells but also F-cells in blood of adults,
as a consequence of differences in the resulting fluorescence
intensity (Figure 1). Nevertheless, our data showed that anti-
HbF caused variable amounts of positive events that were
detected within the gate of fetal red blood cells in blood
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Figure 3: Parallel analysis of results obtained by FCM and ABA. (a) Low correlation (Spearman correlation: r = -0.263, p= 0.039, and n = 57)
and (b) lack of agreement (bias d = 0.342, standard deviation = 0.6047, and confidence interval = 95% [0.842; 1.526] p = 0.559) were found
for the results assessed in blood samples of male adults added with umbilical cord blood at dilutions 1/10, 1/100, 1/1,000, and 1/10,000. (c) No
correlation (Spearman correlation: r = -0.316, p = 0.047, n = 40) and (d) agreement (bias d= 0.233, standard deviation = 0.481, and confidence
interval = 95% [-0.727; 0.397] p = 0.573) were found for the results assessed in blood samples from puerperal women.
samples of male adults that were not added with umbilical
cord blood. These positive events seem to be adult F-cells,
at which the fluorescence intensity dragged them beyond
the specific gate of adult F-cells. Although detected in low
amounts, these positive events were responsible for certain
loss of linearity of FCM, as dilution of fetal cells in blood
samples of male adult increased (Supplementary Table 2).
FCM has been systematically evaluated for FMH diagno-
sis during the last decade and results have shown its advan-
tages for assessment of fetal red blood cells and/or F-cells
in blood samples [20, 22, 23, 26]. Improved FCM protocols
employing anti-HbF in combination with other monoclonal
antibodies, such as anticarbonic anhydrase or anti-RhD, were
also evaluated [7, 27]. However, volume of fetal blood leakage
in FMH is rarely calculated in daily practice and, therefore,
standard doses of anti-D immunoglobulin, ranging from
250 to 300𝜇g, are administered [26, 28, 29]. These doses
are based on the recommendation to use 25𝜇g of anti-D
immunoglobulin for each ml of fetal blood leaked into the
maternal blood compartment [30]. Without the accurate
evaluation of FMH, this dose can represent an overtreatment.
However, with the use of this protocol, only 0.3 to 1.0% of
treatment fails when the standard doses of immunoglobulin
are employed on the 28th week of gestation and within 72
hours postpartum [21, 31, 32].
Finally, although the predictive positive value specified
for ABA (87.08%, Supplementary Table 2) has initially sug-
gested the ability of this method to detect fetal blood laced
with blood from male adults, our results showed that ABA
overestimates FMH and disagree with FCM on indicating
puerperal women with FMH.
5. Conclusion
ABA is inadequate for being used to screen for or to measure
FMH.
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in detecting fetal blood laced with blood from male adults
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Samples were prepared by serially diluting umbilical cord
blood inwhole blood ofmale adult donors. AUC= area under
curve. (Supplementary Materials)
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